Atopic dermatitis: current treatment options

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Atopic dermatitis is a common chronic genetically determined skin disease with complex pathogenesis. Due to the high prevalence of dermatosis and its progression to severe forms, the issue of new treatment options for this disease is relevant. This review discusses new current treatment options for atopic dermatitis, targeted drugs that allow patients with poorly controlled moderate to severe atopic dermatitis to achieve disease control.

Full Text

Restricted Access

About the authors

E. V. Sokolovsky

Pavlov University

Email: kholodilova83@list.ru
Russian Federation, Saint Petersburg

N. A. Kholodilova

Pavlov University

Author for correspondence.
Email: kholodilova83@list.ru
ORCID iD: 0000-0002-7765-7487
SPIN-code: 7601-0687

Cand. Sci. (Med.), Associate Professor

Russian Federation, Saint Petersburg

K. N. Monakhov

Pavlov University

Email: kholodilova83@list.ru
ORCID iD: 0000-0002-8211-1665
Russian Federation, Saint Petersburg

References

  1. Клинические рекомендации 2021 «Атопический дерматит». URL: https://www.cr.minzdrav.gov.ru/clin_recomend-2021. [Clinical practice guidelines 2021 «Atopic dermatitis». URL: https://www.cr.minzdrav.gov.ru/clin_recomend–2021. (In Russ.)].
  2. Монахов К.Н., Холодилова Н.А. Особенности ведения пациенток с обострением атопического дерматита на фоне беременности. Фарматека. 2018;S1:47–51. [Monakhov K.N., Kholodilova N.A. Features of the management of patients with exacerbation of atopic dermatitis against the background of pregnancy. Farmateka. 2018;S1:47–51. (In Russ.)].
  3. Palmer C.N., Irvine A.D., Terron-Kwiatkowski A., et al. Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. Nat Genet. 2006;38:441–46. doi: 10.1038/ng1767.
  4. McGirtL.Y., BeckL.A. Innate immune defects in atopic dermatitis. J Allergy Clin Immunol. 2006;118:202–8. doi: 10.1016/j.jaci.2006.04.033.
  5. Bao L., Zhang H., Chan L.S. The involvement of the JAK-STAT signaling pathway in chronic inflammatory skin disease atopic dermatitis. JAKSTAT. 2013;2(3):e24137. doi: 10.4161/jkst.24137.
  6. Shi B., Bangayan N.J., Curd E., et al. The skin microbiome is different in pediatric versus adult atopic dermatitis. J Allergy Clin Immunol, 2016;138(4):1233–66. doi: 10.1016/j.jaci.2016.04.053.
  7. Seite S., Flores G.E., Henley J.B., et al. Microbiome of affected and unaffected skin of patients with atopic dermatitis before and after emollient treatment. J Drugs Dermatol. 2014;13(11):1365–72.
  8. Соколовский Е.В., Монахов К.Н., Холодилова Н.А., Домбровская Д.К. Современные подходы к лечению экземы кистей. Клиническая дерматология и венерология. 2011;9(6):40–3. [Sokolovsky E.V., Monakhov K.N., Kholodilova N.A., Dombrovskaya D.K. Modern approaches to the treatment of hand eczema. Klinicheskaya dermatologiya i venerologiya. 2011;9(6):40–3. (In Russ.)].
  9. Wollenberg A., Christen-Zäch S., Taieb A., et al. ETFAD/EADV Eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children. J Eur Acad Dermatol Venereol. 2020;34(12):2717–44. doi: 10.1111/jdv.16892.
  10. Возможности системной терапии атопического дерматита селективными иммунодепрессантами: резолюция рабочего совещания экспертов по профилю «дерматология». Педиатрическая фармакология. 2022;19(2):209–11. [Potential for systemic therapy of atopic dermatitis with selective immunosuppressants: resolution of the working meeting of experts in the field of dermatology. Pediatricheskaya farmakologiya. 2022;19(2):209–11. (In Russ.)].
  11. Bubmann C., Novak N. Systemic therapy of atopic dermatitis. Allergol Sel. 2017;1(1):1–8. doi: 10.5414/ALX01285E.
  12. Paller A.S., Bansal A., Simpson E.L. et al. Clinically meaningful responses to dupilumab in adolescents with uncontrolled moderate-to-severe atopic dermatitis: Post-hoc analyses from a randomized clinical trial. Am J Clin Dermatol. 2020;21(1):119–31. doi: 10.1007/s40257-019-00478-y.
  13. Beck L.A., Deleuran M., Bissonnette R., et al. Dupilumab Provides Acceptable Safety and Sustained Efficacy for up to 4 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis. Am J Clin Dermatol. 2022;23:393–408. doi: 10.1007/s40257-022-00685-0.
  14. Agache I., Akdis C.A., Akdis M., et al. EAACI Biologicals Guidelines-dupilumab for children and adults with moderate-to-severe atopic dermatitis. Allergy. 2021;76(4):988–1009. doi: 10.1111/all.14690.
  15. Guttman-Yassky E., Teixeira H.D, Simpson E.L., et al. Safety and Efficacy of Upadacitinib Monotherapy in Adolescents and Adults with Moderate-to-severe Atopic Dermatitis: Results From 2 Pivotal, Phase 3, Randomized, Double-blinded, Placebo-controlled Studies (Measure Up 1 and Measure Up 2). Oral presentation at: EADVirtual; Oct 29-31, 2020. D3T03.4B.
  16. Reich K., Teixeira H. D., de Bruin-Weller M., et al. Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2021;397(10290):2169–81. doi: 10.1016/S0140-6736(21)00589-4.
  17. Blauvelt A., Teixeira H.D., Simpson E.L., Antonio, et al. Efficacy and Safety of Upadacitinib vs Dupilumab in AdultsWith Moderate-to-Severe Atopic Dermatitis. A Randomized Clinical Trial. JAMA Dermatol. doi: 10.1001/jamadermatol.2021.3023. Published online August 4, 2021.
  18. Silverberg J.I., Simpson E.L., Thyssen J.P., et al. Efficacy and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis: A randomized clinical trial. JAMA Dermatol. 2020;156(8):863–73. doi: 10.1001/jamadermatol.2020.1406.
  19. Reich K., Kabashima K., Peris K., et al. Efficacy and safety of baricitinib combined with topical corticosteroids for treatment of moderate to severe atopic dermatitis: A randomized clinical trial. JAMA Dermatol. 2020;156(12):33–1343. doi: 10.1001/jamadermatol.2020.3260.
  20. Simpson E.L., Lacour J.P., Spelman L. et al. Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials. Br J Dermatol. 2020;183(2):242–55. doi: 10.1111/bjd.18898.
  21. Dawn M.R., Davis M.D., Aaron M., et al. Guidelines of care for the management of atopic dermatitis in adults with phototherapy and systemic therapies. J Am Acad Dermatol. 2023;90(2):43–56. doi: 10.1016/j.jaad.2023.08.102.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download
2. Fig. Algorithm for managing patients with atopic dermatitis

Download (5MB)
Indexing metadata

Copyright (c) 2024 Bionika Media